Hamilton Thomas Edward
SEC Form 4 insider trading activity
Hamilton Thomas Edward has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jul 8, 2026.
On the most recent filing, Hamilton Thomas Edward is listed as Director at Larimar Therapeutics, Inc. Inside the rolling window, Hamilton Thomas Edward reported 2 open-market purchases totaling $667K in LRMR and no open-market sales. The largest disclosed transaction in the window is a purchase of 100,000 LRMR shares on Feb 27, 2026, worth $500K.
Companies traded
Other insiders at LRMR
Insider Buying
$667K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hamilton Thomas Edward made?
Hamilton Thomas Edward has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Hamilton Thomas Edward trade?
Hamilton Thomas Edward has filed SEC Form 4 disclosures for 1 company, including LRMR.
When was Hamilton Thomas Edward's most recent SEC Form 4 filing?
Hamilton Thomas Edward's most recent SEC Form 4 filing on Tracefour is dated Jul 8, 2026.
What is Hamilton Thomas Edward's total buy and sell value in the current window?
Inside the rolling retention window, Hamilton Thomas Edward bought $667K and sold $0 based on SEC Form 4 filings.
What was Hamilton Thomas Edward's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 100,000 LRMR shares on 2026-02-27, worth $500K, per SEC Form 4 filings.